Literature DB >> 31281117

Integrative Proteo-genomic Analysis to Construct CNA-protein Regulatory Map in Breast and Ovarian Tumors.

Weiping Ma1, Lin S Chen2, Umut Özbek3, Sung Won Han4, Chenwei Lin5, Amanda G Paulovich5, Hua Zhong6, Pei Wang7.   

Abstract

Recent development in high throughput proteomics and genomics profiling enable one to study regulations of genome alterations on protein activities in a systematic manner. In this article, we propose a new statistical method, ProMAP, to systematically characterize the regulatory relationships between proteins and DNA copy number alterations (CNA) in breast and ovarian tumors based on proteogenomic data from the CPTAC-TCGA studies. Because of the dynamic nature of mass spectrometry instruments, proteomics data from labeled mass spectrometry experiments usually have non-ignorable batch effects. Moreover, mass spectrometry based proteomic data often possesses high percentages of missing values and non-ignorable missing-data patterns. Thus, we use a linear mixed effects model to account for the batch structure and explicitly incorporate the abundance-dependent-missing-data mechanism of proteomic data in ProMAP. In addition, we employ a multivariate regression framework to characterize the multiple-to-multiple regulatory relationships between CNA and proteins. Further, we use proper statistical regularization to facilitate the detection of master genetic regulators, which affect the activities of many proteins and often play important roles in genetic regulatory networks. Improved performance of ProMAP over existing methods were illustrated through extensive simulation studies and real data examples. Applying ProMAP to the CPTAC-TCGA breast and ovarian cancer data sets, we identified many genome regions, including a few novel ones, whose CNA were associated with protein and or phosphoprotein abundances. For example, in breast tumors, a small region in 8p11.21 was recognized as the second biggest hub in the CNA-phosphoprotein regulatory map, and further investigation of the regulatory targets suggests the potential role of 8p11.21 CNA in perturbing oxygen binding and transport activities in tumor cells. This and other findings from our analyses help to characterize the impacts of CNAs on protein activity landscapes and cast light on the genetic regulation mechanisms underlying these tumors.
© 2019 Ma et al.

Entities:  

Keywords:  CNA-protein/phosphosite regulatory map; CNAI; Proteogenomics; breast cancer; cis-regulation; mass spectrometry; ovarian cancer; penalized mixed effect model; phosphoproteome; statistics; trans protein/phosphosite hubs

Mesh:

Substances:

Year:  2019        PMID: 31281117      PMCID: PMC6692778          DOI: 10.1074/mcp.RA118.001229

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  36 in total

1.  Addressing accuracy and precision issues in iTRAQ quantitation.

Authors:  Natasha A Karp; Wolfgang Huber; Pawel G Sadowski; Philip D Charles; Svenja V Hester; Kathryn S Lilley
Journal:  Mol Cell Proteomics       Date:  2010-04-10       Impact factor: 5.911

2.  The IgLON family in epithelial ovarian cancer: expression profiles and clinicopathologic correlates.

Authors:  Evangelos Ntougkos; Robert Rush; Diane Scott; Tobias Frankenberg; Hani Gabra; John F Smyth; Grant C Sellar
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

3.  Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism.

Authors:  Yanyan Cai; Jonathan Crowther; Tibor Pastor; Layka Abbasi Asbagh; Maria Francesca Baietti; Magdalena De Troyer; Iria Vazquez; Ali Talebi; Fabrizio Renzi; Jonas Dehairs; Johannes V Swinnen; Anna A Sablina
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

4.  p140Cap suppresses the invasive properties of highly metastatic MTLn3-EGFR cells via impaired cortactin phosphorylation.

Authors:  L Damiano; S E Le Dévédec; P Di Stefano; D Repetto; R Lalai; H Truong; J L Xiong; E H Danen; K Yan; F J Verbeek; E De Luca; F Attanasio; R Buccione; E Turco; B van de Water; P Defilippi
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

5.  ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Authors:  Christopher P Mill; Michael D Zordan; S Michael Rothenberg; Jeffrey Settleman; James F Leary; David J Riese
Journal:  Genes Cancer       Date:  2011-08

6.  A penalized EM algorithm incorporating missing data mechanism for Gaussian parameter estimation.

Authors:  Lin S Chen; Ross L Prentice; Pei Wang
Journal:  Biometrics       Date:  2014-01-28       Impact factor: 2.571

7.  PRRX2 as a novel TGF-β-induced factor enhances invasion and migration in mammary epithelial cell and correlates with poor prognosis in breast cancer.

Authors:  Yu-Lin Juang; Yung-Ming Jeng; Chi-Long Chen; Huang-Chun Lien
Journal:  Mol Carcinog       Date:  2016-01-29       Impact factor: 4.784

8.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

9.  Identification of gene expression signature in estrogen receptor positive breast carcinoma.

Authors:  Arvind D Thakkar; Hemanth Raj; Debarshi Chakrabarti; N Saravanan; Bhaskaran Muthuvelan; Arun Balakrishnan; Muralidhara Padigaru
Journal:  Biomark Cancer       Date:  2010-02-11

Review 10.  Microtubules and their role in cellular stress in cancer.

Authors:  Amelia L Parker; Maria Kavallaris; Joshua A McCarroll
Journal:  Front Oncol       Date:  2014-06-18       Impact factor: 6.244

View more
  3 in total

1.  Proteomics Is Not an Island: Multi-omics Integration Is the Key to Understanding Biological Systems.

Authors:  Bing Zhang; Bernhard Kuster
Journal:  Mol Cell Proteomics       Date:  2019-08-09       Impact factor: 5.911

2.  MECHANISTIC AND DATA-DRIVEN MODELS OF CELL SIGNALING: TOOLS FOR FUNDAMENTAL DISCOVERY AND RATIONAL DESIGN OF THERAPY.

Authors:  Paul J Myers; Sung Hyun Lee; Matthew J Lazzara
Journal:  Curr Opin Syst Biol       Date:  2021-06-09

3.  Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers.

Authors:  Hee-Sung Ahn; Jung Yoon Ho; Jiyoung Yu; Jeonghun Yeom; Sanha Lee; Soo Young Hur; Yuyeon Jung; Kyunggon Kim; Youn Jin Choi
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.